AR049497A1 - Derivados indolicos como moduladores del receptor x del higado; composiciones farmaceuticas y metodos de preparacion - Google Patents
Derivados indolicos como moduladores del receptor x del higado; composiciones farmaceuticas y metodos de preparacionInfo
- Publication number
- AR049497A1 AR049497A1 ARP050101717A ARP050101717A AR049497A1 AR 049497 A1 AR049497 A1 AR 049497A1 AR P050101717 A ARP050101717 A AR P050101717A AR P050101717 A ARP050101717 A AR P050101717A AR 049497 A1 AR049497 A1 AR 049497A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- aryl
- hydroxy
- carbon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Los compuestos pertenecen a la categoría de derivados de indol utilizados como antidiabéticos y antihiperlipidémicos por su accion moduladora del receptor X del hígado. Procedimientos de obtencion de los mismos. Composiciones farmacéuticas que los contienen. Reivindicacion 1: Compuestos de formula (1), en donde: R1 es hidrogeno, alquilo, halogeno, formilo, hidroxialquilo o trifluorometilo; R2 es hidrogeno, alquilo, alquenilo, alquinilo, ciano o halogeno; R3 es hidrogeno o alquilo; R4 es hidrogeno, alquilo, hidroxi o alcoxi; R5 y R6 son independientemente seleccionados a partir de hidrogeno, alquilo, arilalquilo, heteroarilalquilo, hidroxialquilo, alcoxicarbonilo, arilo y heteroarilo; A es arilo o heterociclilo, en donde arilo y heterociclilo son opcionalmente sustituidos con 1 a 3 sustituyentes independientemente seleccionados a partir de alquilo, halogeno, amino, hidroxialquilo, arilo, ariloxi, alcoxi, arilalquilo, arilalquenilo, alcoxicarbonilamino, aminocarboniloxi, carboxi, alcoxicarbonilo, alcoxicarbonilalquilo, aminoalquilo, trifluorometilo, arilalquilaminocarbonilo, alcoxicarbonilalquilaminocarbonilo, indolilalquilaminocarbonilo, morfolinilcarbonilo, aminocarbonilo, aminocarbonilalquilo, aminocarbonilalcoxi, alcoxicarbonilalcoxi, piridinilalquilaminocarbonilo, alquiloxicarbonilalquilarilo, alquiloxicarbonilalcoxiarilo, carboxialquilarilo, carboxialcoxiarilo, aminocarbonilalquilarilo, aminocarbonilalcoxiarilo, aminocarbonilamino, aminocarboniloxi, aminocarboniloxiarilo, carboxialquilo, carboxialcoxi, cicloalquilaminocarbonilo, morfolinilcarboniloxiarilo, morfolinilcarbonilarilo, arilalcoxiarilo, aminocarbonilarilo, pirrolidinilcarboniloxiarilo, pirrolidinilcarbonilarilo, piperidinilcarbonilarilo, piperidinilcarboniloxiarilo; hidroxialquilarilo, hidroxi(carboxi)alquilarilo, hidroxi(alcoxicarbonil)alquilarilo, hidroxi(aminocarbonil)alquilarilo y piridinilo; m es 0, 1, 2 o 3; n es 0 o 1; p es 0, 1, 2 o 3; con la condicion que la suma de m, n y p es 1, 2, 3 o 4; y, en donde el compuesto no es 2-(1-bencil-2,3-dihidro-1H-indol-5-il)-1,1,1,3,3,3-hexafluoro-propan-2-ol; y, en donde el enlace entre los átomos de carbono Ca y Cb es un carbono-carbono simple o doble enlace y en el caso que el enlace Ca y Cb sea un doble enlace carbono-carbono R3 y R4 están ausentes; y sales farmacéuticamente aceptables y ésteres farmacéuticamente aceptables de éstos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101889 | 2004-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049497A1 true AR049497A1 (es) | 2006-08-09 |
Family
ID=34970495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101717A AR049497A1 (es) | 2004-05-03 | 2005-04-29 | Derivados indolicos como moduladores del receptor x del higado; composiciones farmaceuticas y metodos de preparacion |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7173048B2 (es) |
| EP (1) | EP1756096B1 (es) |
| JP (1) | JP4682192B2 (es) |
| KR (1) | KR100893449B1 (es) |
| CN (1) | CN1950365A (es) |
| AR (1) | AR049497A1 (es) |
| AT (1) | ATE439357T1 (es) |
| AU (1) | AU2005238176B2 (es) |
| BR (1) | BRPI0510599A (es) |
| CA (1) | CA2564563C (es) |
| DE (1) | DE602005015962D1 (es) |
| DK (1) | DK1756096T3 (es) |
| ES (1) | ES2329489T3 (es) |
| HR (1) | HRP20090533T1 (es) |
| IL (1) | IL178767A0 (es) |
| MX (1) | MXPA06012683A (es) |
| MY (1) | MY139571A (es) |
| NO (1) | NO20065503L (es) |
| NZ (1) | NZ550447A (es) |
| PL (1) | PL1756096T3 (es) |
| PT (1) | PT1756096E (es) |
| RU (1) | RU2368612C2 (es) |
| SI (1) | SI1756096T1 (es) |
| TW (1) | TWI287537B (es) |
| WO (1) | WO2005105791A1 (es) |
| ZA (1) | ZA200608886B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080682B2 (en) | 2006-08-24 | 2011-12-20 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US20070219206A1 (en) * | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US8399666B2 (en) * | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US20070244128A1 (en) * | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) * | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US7977359B2 (en) * | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| WO2008042571A2 (en) * | 2006-09-29 | 2008-04-10 | Smithkline Beecham Corporation | Substituted indole compounds |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| EP2144902B1 (en) * | 2007-05-04 | 2012-05-16 | Bristol-Myers Squibb Company | [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| PE20090213A1 (es) | 2007-05-04 | 2009-02-28 | Bristol Myers Squibb Co | Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos |
| WO2009012277A1 (en) | 2007-07-17 | 2009-01-22 | Bristol-Myers Squibb Company | Method for modulating gpr119 g protein-coupled receptor and selected compounds |
| KR100918814B1 (ko) * | 2007-10-04 | 2009-09-25 | 건국대학교 산학협력단 | 인쇄방법을 이용한 세라믹 전자부품 고속제조방법 |
| TW200920369A (en) * | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
| CA2716877A1 (en) * | 2008-03-17 | 2009-09-24 | F. Hoffmann-La Roche Ag | Lxr ligand binding domain (lxr lbd) crystals |
| JP5791500B2 (ja) * | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ，エルエルシー． | ５−リポキシゲナーゼ活性化タンパク質阻害剤 |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| SG184168A1 (en) | 2010-04-08 | 2012-10-30 | Bristol Myers Squibb Co | Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators |
| EP2566862B1 (en) | 2010-05-06 | 2015-09-16 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| MX2012012902A (es) | 2010-05-06 | 2012-12-17 | Bristol Myers Squibb Co | Analogos heteroarilo biciclicos como moduladores de receptor acoplado a la proteina g gpr119. |
| MX351305B (es) * | 2011-01-20 | 2017-10-09 | Merck Sharp & Dohme | Antagonistas del receptor de mineralocorticoides. |
| EP2850073B1 (en) | 2012-05-16 | 2017-07-19 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| IN2015DN01046A (es) | 2012-07-13 | 2015-06-26 | Gtx Inc | |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| WO2015061272A1 (en) | 2013-10-22 | 2015-04-30 | Bristol-Myers Squibb Company | Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| CN106187899B (zh) * | 2016-06-28 | 2019-07-16 | 绍兴文理学院 | 一种氟代氮杂芳烃的合成方法 |
| EP3487862A1 (en) | 2016-07-22 | 2019-05-29 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
| TWI748194B (zh) * | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
| US20200085810A1 (en) | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| CN110305141B (zh) * | 2019-07-18 | 2022-01-11 | 深圳市三启药物开发有限公司 | 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用 |
| RS65646B1 (sr) | 2019-12-13 | 2024-07-31 | Inspirna Inc | Soli metala i njihove upotrebe |
| CN115028655B (zh) * | 2022-05-20 | 2024-01-16 | 上海大学 | 一种2-三氟甲基-3-碘-吲哚类化合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4251659A (en) * | 1977-12-22 | 1981-02-17 | E. I. Du Pont De Nemours And Company | Polyfluorohydroxyisopropyl-heterocyclic compounds |
| GR63361B (en) * | 1976-06-24 | 1979-10-22 | Du Pont | Preparation process of antihypertensive hexafluorohydroxyisopropyl bicyclic and tricyclic carbostyrils |
| JPH0995482A (ja) | 1995-09-29 | 1997-04-08 | Shionogi & Co Ltd | α−置換酢酸を有する複素環誘導体、その製造用中間体ならびにそれを含有する農薬 |
| WO1997019311A1 (en) | 1995-11-17 | 1997-05-29 | Form Rite | Bypass fitting for a transmission fluid cooler |
| RU2278859C2 (ru) | 2001-05-15 | 2006-06-27 | Ф.Хоффманн-Ля Рош Аг | Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета |
| US6472386B1 (en) | 2001-06-29 | 2002-10-29 | Kowa Co., Ltd. | Cyclic diamine compound with 5-membered ring groups |
| GB0216224D0 (en) | 2002-07-12 | 2002-08-21 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-04-26 PT PT05751959T patent/PT1756096E/pt unknown
- 2005-04-26 JP JP2007511949A patent/JP4682192B2/ja not_active Expired - Fee Related
- 2005-04-26 EP EP05751959A patent/EP1756096B1/en active Active
- 2005-04-26 WO PCT/EP2005/004454 patent/WO2005105791A1/en active Application Filing
- 2005-04-26 KR KR1020067023014A patent/KR100893449B1/ko not_active IP Right Cessation
- 2005-04-26 CA CA2564563A patent/CA2564563C/en not_active Expired - Fee Related
- 2005-04-26 MX MXPA06012683A patent/MXPA06012683A/es active IP Right Grant
- 2005-04-26 CN CNA2005800142069A patent/CN1950365A/zh active Pending
- 2005-04-26 SI SI200530765T patent/SI1756096T1/sl unknown
- 2005-04-26 NZ NZ550447A patent/NZ550447A/en not_active IP Right Cessation
- 2005-04-26 BR BRPI0510599-4A patent/BRPI0510599A/pt not_active IP Right Cessation
- 2005-04-26 DK DK05751959T patent/DK1756096T3/da active
- 2005-04-26 AT AT05751959T patent/ATE439357T1/de active
- 2005-04-26 DE DE602005015962T patent/DE602005015962D1/de active Active
- 2005-04-26 RU RU2006142746/04A patent/RU2368612C2/ru not_active IP Right Cessation
- 2005-04-26 ES ES05751959T patent/ES2329489T3/es active Active
- 2005-04-26 AU AU2005238176A patent/AU2005238176B2/en not_active Ceased
- 2005-04-26 PL PL05751959T patent/PL1756096T3/pl unknown
- 2005-04-27 US US11/115,942 patent/US7173048B2/en not_active Expired - Fee Related
- 2005-04-28 MY MYPI20051897A patent/MY139571A/en unknown
- 2005-04-29 AR ARP050101717A patent/AR049497A1/es unknown
- 2005-04-29 TW TW094113966A patent/TWI287537B/zh not_active IP Right Cessation
-
2006
- 2006-10-19 IL IL178767A patent/IL178767A0/en unknown
- 2006-10-25 ZA ZA200608886A patent/ZA200608886B/en unknown
- 2006-11-29 NO NO20065503A patent/NO20065503L/no not_active Application Discontinuation
- 2006-12-11 US US11/636,925 patent/US7485652B2/en not_active Expired - Fee Related
-
2009
- 2009-10-02 HR HR20090533T patent/HRP20090533T1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049497A1 (es) | Derivados indolicos como moduladores del receptor x del higado; composiciones farmaceuticas y metodos de preparacion | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20071177A1 (es) | Derivados de 3,5-piridina como inhibidores de renina | |
| BRPI0413233A (pt) | novos compostos | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| PE20080997A1 (es) | Compuestos n-fenilmetil-5-oxo-prolina-2-amida como moduladores de receptores p2x7 | |
| CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
| MX2009006878A (es) | Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas. | |
| BRPI0414817A (pt) | derivados de ácido indol substituìdos e seu uso como inibidores de pai-l | |
| PE20010641A1 (es) | Derivados de piperazina como antagonistas del receptor de serotonina 5-ht1b | |
| TW200635897A (en) | Piperidine derivatives and their use as anti-inflammatory agents | |
| MX2009014208A (es) | Compuestos heterociclicos y usos de los mismos como inhibidores de erk. | |
| RS52700B (en) | SUBSTITUTED OXINDOL DERIVATIVE AND ITS USE AS A VASOPRESIN RECEPTOR LIGAND | |
| PE20091095A1 (es) | Moduladores de gamma secretasa | |
| NZ543722A (en) | Novel substituted 3-sulfur indoles | |
| HK1110868A1 (en) | Heterocyclic compounds as ccr2b antagonists | |
| PE20090441A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA | |
| TW200612936A (en) | Indole derivatives | |
| ES2567311T3 (es) | 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP | |
| MX2010000658A (es) | Derivados de pirimidina 934. | |
| AR028817A1 (es) | Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen | |
| TW200833694A (en) | Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety | |
| DK1153017T3 (da) | Bicykliske forbindelser og deres anvendelse som integrinreceptorligander | |
| PL1831152T3 (pl) | Pochodne tetraliny i indanu oraz ich zastosowanie jako antagonistów 5-HT | |
| AR054083A1 (es) | Compuestos imidazol y su utilizacion paar preparar medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |